4-[(5R)-5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]benzamide

Base Information

• Chemical Name: 4-[(5R)-5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]benzamide
• CAS No.: 864731-61-3
• Molecular Formula: C₂₂H₁₇Cl₂F₆N₃O₃
• Molecular Weight: 556.292
• Mol file: 864731-61-3.mol

Synonyms:

Chemical Property of 4-[(5R)-5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]benzamide

Chemical Property:

• PKA: 12.50±0.46(Predicted)
• Density: 1.51±0.1 g/cm3(Predicted)

Purity/Quality:

98% min ^*data from raw suppliers

Fluralaner ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

Useful:

• Description: Fluralaner (INN) is a systemic insecticide and acaricide that is administered orally. The U.S. Food and Drug Administration (FDA) approved it under the trade name Bravecto for flea treatment in dogs in May 2014. The EU approved the drug in February 2014. Australia approved it for the treatment and prevention of ticks and fleas on dogs in January 2015.
• Uses: Fluralaner is an insecticide and acaricide used to treat Sarcoptes scabiei var. canis infestation in dogs. Flea treatment. A possible anti-malarial found to kill disease-spreading mosquitoes when they bite treated people. Fluralaner is a novel systemically administered insecticidal and acaricidal compound that provides long-acting efficacy after oral administration to dogs. Fluralaner belongs to a new class of compounds, the isoxazolines. A field study has shown that a single fluralaner dose administered orally to dogs provides at least twelve weeks of flea- and tick-control. The long duration of activity offers a more convenient treatment over monthly flea and tick control treatments with a potential compliance advantage, reducing the risk of vector-transmitted diseases.
• Drug interactions: Fluralaner is highly bound to plasma proteins and might compete with other highly bound drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and the cumarin derivative warfarin. Incubation of fluralaner in the presence of carprofen or warfarin in dog plasma at maximum expected plasma concentrations did not reduce the protein binding of fluralaner, carprofen or warfarin. During clinical field testing, no interactions between Bravecto chewable tablets for dogs and routinely used veterinary medicinal products were observed.

Technology Process of 4-[(5R)-5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]benzamide

There total 42 articles about 4-[(5R)-5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]benzamide which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 94.12%

4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methylbenzoic acid (864725-62-2) + 2-ammonia-N-(2,2,2-trifluoroethyl)acetamide (359821-38-8) → A1443 (864731-61-3)

Guidance literature:

4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methylbenzoic acid; With diphenyl phosphoryl azide; triethylamine; In N,N-dimethyl-formamide; for 1h; Cooling with ice;

2-ammonia-N-(2,2,2-trifluoroethyl)acetamide; In N,N-dimethyl-formamide; at 20 ℃; Product distribution / selectivity;

Reference yield: 92.1%

1,3-dichloro-5-(3,3,3-trifluoroprop-1-en-2-yl)benzene (864725-22-4) + C13H13ClF3N3O3 → A1443 (864731-61-3)

Guidance literature:

With triethylamine; In N,N-dimethyl-formamide; at 20 ℃; for 14h;

Reference yield: 88.6%

4-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-2-methyl-benzonitrile (930110-37-5) + 2-ammonia-N-(2,2,2-trifluoroethyl)acetamide (359821-38-8) → A1443 (864731-61-3)

Guidance literature:

With hydroxylamine hydrochloride; zinc trifluoromethanesulfonate; In 5,5-dimethyl-1,3-cyclohexadiene; water; at 110 ℃; for 8h; Sealed tube;

upstream raw materials:

trifluoroethylamine

carbon monoxide

2-ammonia-N-(2,2,2-trifluoroethyl)acetamide

4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methylbenzoic acid

Refernces

• 1、 -. "PROCESS FOR PREPARATION OF ISOXAZOLINE SUBSTITUTED BENZAMIDE COMPOUND". . . Retrieved 2022/03/14.
• 2、 -. "Fluorine thramine intermediate and method for preparing flumbine by using same". . . Retrieved 2021/12/07.